Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autogene Cevumeran + Atezolizumab + mFOLFIRINOX in Resected Pancreatic Ductal Adenocarcinoma
NCT05968326Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Oct 2023
- Primary completion
- Jan 2031
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 10
01
Overview
A Phase 2 trial of autogene cevumeran in pancreatic ductal adenocarcinoma (PDAC), sponsored by Genentech. Started Oct 2023; status: active, not recruiting.
02
Drugs
autogene cevumeran
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05968326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968326.